Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

ABT-494

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by a heterogeneous clinical response to the different… Expand
Highly Cited
2018
Highly Cited
2018
BackgroundAnti-cytokine therapies such as adalimumab, tocilizumab, and the small molecule JAK inhibitor tofacitinib have proven… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2016
Highly Cited
2016
To evaluate the efficacy and safety of ABT‐494, a selective JAK‐1 inhibitor, in patients with moderate‐to‐severe rheumatoid… Expand
Highly Cited
2016
Highly Cited
2016
To compare the efficacy and safety of ABT‐494, a novel selective JAK‐1 inhibitor, with placebo in patients with moderate‐to… Expand
Highly Cited
2016
Highly Cited
2016
BackgroundABT-494 is a potent and selective Janus kinase (JAK) 1 inhibitor being developed for the treatment of several… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Review
2016
Review
2016
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by synovial inflammation and joint destruction… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Review
2016
Review
2016
Background ABT-494 is a novel selective JAK1 inhibitor. Objectives The safety, efficacy, and dose response of ABT-494 were… Expand
Review
2014
Review
2014
  • P. Norman
  • Expert opinion on investigational drugs
  • 2014
  • Corpus ID: 21143324
Introduction: The JAK kinases are a family of four tyrosine receptor kinases that play a pivotal role in cytokine receptor… Expand
2014
2014
Background Anti-cytokine therapies have become the mainstay of treatment for rheumatoid arthritis (RA) disease symptoms and can… Expand